Where RPT Realty Stands With Analysts

Analysts have provided the following ratings for RPT Realty (NYSE:RPT) within the last quarter:

Analysts have provided the following ratings for RPT Realty (NYSE:RPT) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 1 1 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 0 1 1 0 0
3M Ago 1 0 0 0 0

According to 4 analyst offering 12-month price targets in the last 3 months, RPT Realty has an average price target of $12.25 with a high of $13.00 and a low of $11.00.

Below is a summary of how these 4 analysts rated RPT Realty over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 12.5% from the previous average price target of $14.00.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

What’s Going On With Crispr Therapeutics Stock?

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have risen nearly 37% over the past month following the FDA approval of Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older on Jan. 16.

CRSP